Tobevibart + Elebsiran
Phase 3Active 0 views this week 0 watching💤 Quiet
Interest: 38/100
38
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Viral Hepatitis
Conditions
Viral Hepatitis
Trial Timeline
Mar 12, 2025 → May 1, 2031
NCT ID
NCT06903338About Tobevibart + Elebsiran
Tobevibart + Elebsiran is a phase 3 stage product being developed by Vir Biotechnology for Viral Hepatitis. The current trial status is active. This product is registered under clinical trial identifier NCT06903338. Target conditions include Viral Hepatitis.
What happened to similar drugs?
1 of 5 similar drugs in Viral Hepatitis were approved
Approved (1) Terminated (1) Active (3)
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06903338 | Phase 3 | Active |
Competing Products
17 competing products in Viral Hepatitis